ATRS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ATRS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Antares Pharma's total inventories for the quarter that ended in Mar. 2022 was $11.6 Mil. Antares Pharma's average total inventories from the quarter that ended in Dec. 2021 to the quarter that ended in Mar. 2022 was $11.6 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Antares Pharma's Net-Net Working Capital per share for the quarter that ended in Mar. 2022 was $0.19.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Antares Pharma's Days Inventory for the three months ended in Mar. 2022 was 56.24.
Inventory Turnover measures how fast the company turns over its inventory within a year. Antares Pharma's Inventory Turnover for the quarter that ended in Mar. 2022 was 1.62.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Antares Pharma's Inventory-to-Revenue for the quarter that ended in Mar. 2022 was 0.28.
The historical data trend for Antares Pharma's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Antares Pharma Annual Data | |||||||||||||||||||||
Trend | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | |||||||||||
Total Inventories | Get a 7-Day Free Trial | 9.28 | 11.35 | 16.00 | 18.22 | 11.54 |
Antares Pharma Quarterly Data | ||||||||||||||||||||
Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | |
Total Inventories | Get a 7-Day Free Trial | 19.61 | 18.64 | 16.49 | 11.54 | 11.59 |
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Antares Pharma (NAS:ATRS) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Antares Pharma's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2022 is
Net-Net Working Capital Per Share (Q: Mar. 2022 ) | |||||||
= | (Cash And Cash Equivalents | + | 0.75 * Accounts Receivable | + | 0.5 * Total Inventories | - | Total Liabilities |
- | Preferred Stock | - | Minority Interest) | / | Shares Outstanding (EOP) | ||
= | (62.213 | + | 0.75 * 58.131 | + | 0.5 * 11.591 | - | 79.89 |
- | 0 | - | 0) | / | 170.58 | ||
= | 0.19 |
2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Antares Pharma's Days Inventory for the three months ended in Mar. 2022 is calculated as:
Days Inventory | = | Average Total Inventories (Q: Mar. 2022 ) | / | Cost of Goods Sold (Q: Mar. 2022 ) | * | Days in Period |
= | 11.5675 | / | 18.767 | * | 365 / 4 | |
= | 56.24 |
3. Inventory Turnover measures how fast the company turns over its inventory within a year.
Antares Pharma's Inventory Turnover for the quarter that ended in Mar. 2022 is calculated as
Inventory Turnover | = | Cost of Goods Sold (Q: Mar. 2022 ) | / | Average Total Inventories (Q: Mar. 2022 ) |
= | 18.767 | / | 11.5675 | |
= | 1.62 |
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Antares Pharma's Inventory to Revenue for the quarter that ended in Mar. 2022 is calculated as
Inventory-to-Revenue | = | Average Total Inventories (Q: Mar. 2022 ) | / | Revenue (Q: Mar. 2022 ) |
= | 11.5675 | / | 41.557 | |
= | 0.28 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Thank you for viewing the detailed overview of Antares Pharma's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.
Karen L. Smith | director | C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2 |
Carmen B Volkart | director | C/O MODULAR MEDICAL, INC., 16772 WEST BERNARDO DRIVE, SAN DIEGO CA 92127 |
Peter C Richardson | officer: See Remarks | 28903 NORTH AVENUE PAINE, VALENCIA CA 91355 |
Fred M Powell | officer: Executive Vice President & CFO | C/O BEJING MED-PHARM CORPORATION 600 W. GERMANTOWN PIKE, SUITE 400 PLYMOUTH MEETING PA 19462 |
Thomas J Garrity | director | |
Roche Robert P Jr | director | 41 MOORES ROAD FRAZER PA 19355 |
Leonard S Jacob | director | C/O INKINE PHARMACEUTICAL COMPANY INC 425 PARK AVENUE NEW YORK NY 10022 |
Peter J Graham | officer: See Remarks | 315 E. 72ND ST., APT 5E, NEW YORK NY 10021 |
Peter Greenleaf | director | ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878 |
Anton Gueth | director | |
Robert F Apple | director, officer: President & CEO | C/O INKLINE PHARMACEUTICAL CO INC SENTRY PARK EAST 1720 WALTON ROAD BLUE BELL PA 19422 |
Marvin Samson | director | |
Jacques Gonella | director | C/O ANTARES PHARMA INC 707 EAGLEVIEW BLVD SUITE 414 EXTON PA 19341 |
James Patrick Tursi | officer: EVP, Chief Medical Officer | 106 ASHLEY COURT, MOORESTOWN NJ 08057 |
Keith E Muckenhirn | officer: VP/Controller & Interim CFO | C/O ANTARES PHARMA, INC. 3905 ANNAPOLIS LANE N, SUITE 105 PLYMOUTH MN 55447 |
From GuruFocus
By GuruFocus Research GuruFocus Editor • 08-15-2022
By PRNewswire PRNewswire • 06-08-2022
By PRNewswire PRNewswire • 04-13-2022
By PRNewswire PRNewswire • 06-05-2022
By Business Wire Business Wire • 05-05-2022
By Business Wire Business Wire • 05-02-2022
By PRNewswire PRNewswire • 04-28-2022
By GuruFocusNews GuruFocusNews • 04-13-2022
By GuruFocus Research GuruFocus Editor • 07-29-2022
By PRNewswire PRNewswire • 05-12-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.